Three-dimensional structure of a complex of galanthamine (Nivalin®) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti-Alzheimer drugs

Proteins: Structure, Function and Genetics

Volumn 42, Issue 2, 2001, Pages 182-191

  Bartolucci, Cecilia ^a   Perola, Emanuele ^b   Pilger, Christian ^c   Fels, Gregor ^c   Lamba, Doriano ^a,d  

^a Istituto di Strutturistica Chimica 'G Giacomello'   (Italy)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PADERBORN   (Germany)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Drug design; Protein crystallography

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; GALANTAMINE;

ALLOSTERISM; ALZHEIMER DISEASE; BINDING AFFINITY; BINDING SITE; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME STRUCTURE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; STRUCTURE ANALYSIS; TORPEDO CALIFORNICA; X RAY ANALYSIS; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BINDING SITES; CHOLINESTERASE INHIBITORS; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; CYCLOHEXANES; CYCLOHEXENES; DRUG DESIGN; GALANTAMINE; MODELS, MOLECULAR; NOOTROPIC AGENTS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TORPEDO;

EID: 0035254937     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0134(20010201)42:2<182::AID-PROT50>3.0.CO;2-1     Document Type: Conference Paper

References (49)

1. Alzheimer's disease: The amyloid cascade hypothesis
2. Biochemistry of altered brain proteins in Alzheimer's disease
3. New approach to drug therapy in Alzheimer's dementia
4. Tacrine
5. The rationale for E2020 as a potent acetylcholinesterase inhibitor
6. The pharmacology of galanthamine and its analogues
7. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group
8. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group
9. Development of a pilot scale process for the anti-Alzheimer drug (-)-galanthamine using large scale phenolic oxidative coupling and crystallization-induced chiral conversion
10. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
11. Galanthamine derivatives for the treatment of Alzheimer's disease
12. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A
13. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase
14. Static Laue diffraction studies on acetylcholinesterase
15. Structure of acetylcholinesterase complexed with E2020 (Aricept®): Implications for the design of new anti-Alzheimer drugs
16. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase
17. "Back door" opening implied by the crystal structure of carbamoylated acetylcholinesterase
18. Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking
19. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution
20. Purification and crystallization of a dimeric form of acetylcholinesterase from Torpedo californica subsequent to solubilization with phosphatidylinositol-specific phospholipase C
21. Processing of X-ray diffraction data collected in oscillation mode
22. The CCP4 Suite: Programs for protein crystallography
23. The protein data bank
24. Spectroscopic studies of galanthamine and galanthamine methiodide
25. Improved methods for building protein models in electron density maps and location of errors in these models
26. Accurate bond and angle parameters for X-ray protein structure refinement
27. Automated docking of substrates to proteins by simulated annealing
28. (-)-Galanthaminium bromide
29. A second generation force field for the simulation of proteins and nucleic acids
30. GRASP: Graphical representation and analysis of surface properties
31. Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica
32. Pharmacokinetics of galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats
33. Aromatic rings act as hydrogen bond acceptors
34. A modular treatment of molecular traffic through the active site of cholinesterase
35. Rapid binding of a cationic active site inhibitor to wilde type and mutant mouse acetylcholinesterase: Brownian dynamics simulation including diffusion in the active site gorge
36. Acetylthiocholine binds to Asp74 at the peripheral site of human acetylcholinesterase as the first step in the catalytic pathway
37. Potent acetylcholinesterase inhibitors: Design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series
38. Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease?
39. Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia
40. Synthesis and structure-activity relationships of new acetylcholinesterase inhibitors: Morpholinoalkylcarbamoyloxyeseroline derivatives
41. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: New insights into the mechanism of action in the inhibition of acetylcholinesterase
42. Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp
43. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis
44. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly
45. Crystal structures of native and E202Q mutant human acetylcholinesterase complexed with fasciculin-II